The primary endpoint of this phase II study that evaluated the efficacy and safety of the investigational compound, AGS-16C3F, versus axitinib in previosuly treated patients with metastatic renal cell carcinoma (mRCC) was not met.
The primary endpoint of this phase II study that evaluated the efficacy and safety of the investigational compound, AGS-16C3F, versus axitinib in previosuly treated patients with metastatic renal cell carcinoma (mRCC) was not met.